AnaptysBio, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-29$33.94 RISE2026-01-05$28.80 PEAK2026-03-17$44.86 78d | -15.1% 7d | Missed | Missed | — | — | +55.8% 71d | Missed |
DROP2025-11-07$26.43 RISE2025-11-12$22.06 PEAK2026-02-03$34.14 88d | -16.5% 5d | Missed | Missed | — | — | +54.8% 83d | Missed |
DROP2025-07-23$18.00 RISE2025-09-16$12.93 PEAK2025-12-10$29.97 140d | -28.1% 55d | Missed | Missed | — | — | +131.7% 85d | Missed |
DROP2024-10-21$23.58 RISE2025-02-11$8.25 PEAK2025-04-30$14.81 191d | -65.0% 113d | Missed | Missed | — | — | +79.6% 78d | Missed |
DROP2024-09-13$26.89 RISE2024-12-27$8.69 PEAK2025-02-14$14.15 154d | -67.7% 105d | Missed | Missed | — | — | +62.7% 49d | Missed |
DROP2024-02-27$17.65 RISE2024-04-25$12.58 PEAK2024-07-23$24.64 147d | -28.7% 58d | Missed | Missed | — | — | +95.9% 89d | Missed |
DROP2023-08-01$13.71 RISE2023-11-28$9.23 PEAK2024-02-26$17.64 209d | -32.6% 119d | Missed | Missed | — | — | +91.0% 90d | Missed |
DROP2023-06-28$13.87 RISE2023-09-22$11.25 PEAK2023-10-09$13.30 103d | -18.9% 86d | Missed | Missed | — | — | +18.3% 17d | Missed |
DROP2023-04-19$15.25 RISE2023-07-27$11.16 PEAK2023-08-01$13.71 104d | -26.8% 99d | Missed | Missed | — | — | +22.8% 5d | Missed |
DROP2022-12-29$20.99 RISE2023-01-11$14.23 PEAK2023-02-17$17.99 50d | -32.2% 13d | Missed | Missed | — | — | +26.4% 37d | Missed |
DROP2022-03-09$20.63 RISE2022-07-11$12.89 PEAK2022-10-04$17.98 209d | -37.5% 124d | Missed | Missed | — | — | +39.5% 85d | Missed |
DROP2022-01-25$21.67 RISE2022-06-02$12.47 PEAK2022-08-12$17.49 199d | -42.4% 128d | Missed | Missed | — | — | +40.2% 71d | Missed |
DROP2021-11-08$24.97 RISE2021-12-10$20.00 PEAK2021-12-23$24.71 45d | -19.9% 32d | Missed | Missed | — | — | +23.6% 13d | Missed |
DROP2021-11-08$24.97 RISE2021-12-09$20.00 PEAK2021-12-23$24.71 45d | -19.9% 31d | Missed | Missed | — | — | +23.6% 14d | Missed |
DROP2021-02-12$23.49 RISE2021-06-04$15.20 PEAK2021-06-25$17.63 133d | -35.3% 112d | Missed | Missed | — | — | +16.0% 21d | Missed |
1–15 / 19 1 / 2 | |||||||
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Forte Biosciences (FBRX) surged on 2026 FB102 data hopes. See here for Phase 1b celiac results, competition risks, valuation vs. cash, and outlook.
Grupo Traxión is in focus after a major global bank cut its MX$ price target by MX$6, pointing to a more restrained view on the stock. The shift lines up with recent research that adopts a more cautious tone on parts of the story, even as some analysts keep a constructive stance. As you read on, you will see how this evolving narrative could shape the way you track and interpret future updates around the stock. Stay updated as the Fair Value for Grupo Traxión. de shifts by adding it to your...
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and raises the price target from $60 to $76.
Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and raises the price target from $63 to $75.
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations businessNow exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with...
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(1.84) per share which missed the analyst consensus estimate of $(0.92) by 100 percent. This is a 43.75 percent decrease over losses of $(1.28) per share from the
Rocket Pharmaceuticals shares fell after a wider-than-expected Q1 loss as the company focuses on the launch of newly approved gene therapy Kresladi.
AnaptysBio Inc: Anaptys appoints Chris Murphy as chief financial officer Owen Hughes appointed to board of directors...
AnaptysBio, Inc. (NASDAQ:ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial
Conference spotlight after royalty pivot AnaptysBio (ANAB) is set to present at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on May 6, following its recent spinoff of First Tracks Biotherapeutics and shift to a royalty focused model. See our latest analysis for AnaptysBio. The stock has had a strong run, with a 90 day share price return of 34.65% and a 1 year total shareholder return of 413.05%. This suggests momentum has been building as investors react to the royalty...
AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks […]
Presenter SpeechDavid Risinger So thanks, everybody, for joining. My name is Dave Risinger. Very much pleased to welcome Anaptys, and Dan Faga, the company's CEO. So sorry, we're getting started a
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
MIRM beats Q1 earnings and revenue estimates as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANAB | -16.61% | +52.08% | +72.25% | +275.64% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -19.58% | +57.79% | +75.69% | +262.95% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 992.4K | $55.04M | 0.00% | Trimmed-5.8% | 2026-03-31 |
| DEShaw | quant | 579.3K | $32.13M | 0.02% | Trimmed-13.6% | 2026-03-31 |
| FidelityFMR | fundamental | 472.7K | $26.22M | 0.00% | Added+1643.8% | 2026-03-31 |
| TwoSigma | quant | 465.1K | $25.79M | 0.02% | Added+81.2% | 2026-03-31 |
| RenTech | quant | 90.9K | $5.04M | 0.01% | Added+19.1% | 2026-03-31 |
| Citadel | multi-strat | 55.3K | $3.07M | 0.00% | Trimmed-97.1% | 2026-03-31 |
| Wellington | fundamental | 46.9K | $2.60M | 0.00% | Trimmed-23.4% | 2026-03-31 |
| TRowePrice | fundamental | 29.7K | $1.65K | 0.00% | Added+14.2% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-05upcoming | 0.39 | — | — |
| 2026-03-03 | 0.93 | 1.58 | +69.26% |
| 2025-11-04 | -1.25 | 0.52 | +141.58% |
| 2025-08-06 | -1.58 | -1.34 | +15.27% |
| 2025-05-05 | -1.46 | -1.28 | +12.53% |
| 2025-02-27 | -1.70 | -0.72 | +57.77% |
| 2024-11-05 | -1.61 | -1.14 | +29.29% |
| 2024-08-05 | -0.93 | -1.71 | -83.48% |
| 2024-05-09 | -1.60 | -1.64 | -2.69% |
| 2024-03-11 | -1.49 | -1.59 | -6.35% |
| 2023-11-02 | -1.89 | -1.41 | +25.43% |
| 2023-08-07 | -1.74 | -1.50 | +13.95% |
| 2023-05-11 | -1.02 | -1.58 | -54.27% |
| 2023-03-01 | -0.94 | -0.93 | +1.30% |
| 2022-11-08 | -0.63 | -1.18 | -88.37% |
| 2022-08-08 | -1.07 | -1.15 | -7.49% |